EUVIMEDEUVIMED entdecken
Crossref

Effectiveness and safety of pembrolizumab as bridging to hematopoietic stem cell transplantation in relapsed and refractory classical Hodgkin’s lymphoma: a retrospective observational study

Rawan Fawzi Al Froukh, Noor Abd Al-Jalil, Nour Faqeer, Mohammad Ma’koseh, Abeer Al-Rabayah

Annals of Lymphoma · 2020

DOI: 10.21037/aol-20-21 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Lymphoma, 2020. Verfasst von Rawan Fawzi Al Froukh und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although pembrolizumab is approved for the treatment of relapsed and refractory classical Hodgkin’s lymphoma, there are limited data regarding its use as bridging to hematopoietic stem cell transplant. Therefore, we aimed to assess the effectiveness and safety of pembrolizumab as bridging to hematopoietic stem cell transplant in relapsed and refractory classical Hodgkin’s lymphoma.

Methods

This is a retrospective study, which included adult chemo-resistant relapsed and refractory classical Hodgkin’s lymphoma patients who received pembrolizumab with the aim of bridging to hematopoietic stem cell transplant. The primary endpoints were effectiveness outcomes expressed as response rate, hematopoietic stem cell transplant rate, 1-year progression-free survival and overall survival. Relapse rate post hematopoietic stem cell transplant, incidences of treatment-related adverse events and graft-versus-host disease were secondary endpoints.

Results

A total of 32 patients were included, the median age was 29.5 years (range, 18.0–53.0 years), and around 59% were male. Patients received a median of 5 pembrolizumab cycles (range, 1–8). The median follow-up duration was 11.6 months (range, 6.7–27.4 months). The response was assessable in 29 patients, 78% of the patients responded to pembrolizumab, 17 (53%) underwent hematopoietic stem cell transplant (autologous: 11, allogeneic: 6) with a 1-year progression-free survival and overall survival of 85% and 91%, respectively. Five patients (29%) relapsed after hematopoietic stem cell transplant, two of them (18%) relapsed post-autologous stem cell transplant (ASCT) and three patients (50%) relapsed after allogeneic stem cell transplant (Allo-SCT). Treatment-related adverse events were reported in 66% of patients with dermatologic reactions, pneumonitis, and infections being the most common reported treatment-related adverse events. Acute graft-versus-host disease occurred in 83.3% of allogeneic transplanted patients, which was fatal in one patient. Three patients (60%) developed chronic graft-versus-host disease in addition to the acute episodes.

Conclusions

Pembrolizumab showed a promising role as bridging to ASCT in chemo-resistant relapsed and refractory classical Hodgkin’s lymphoma patients rather than to Allo-SCT. These findings require further investigation in larger prospective studies.

Zitieren

APA

Froukh, R. F. A., Al-Jalil, N. A., Faqeer, N., Ma’koseh, M., & Al-Rabayah, A. (2020). Effectiveness and safety of pembrolizumab as bridging to hematopoietic stem cell transplantation in relapsed and refractory classical Hodgkin’s lymphoma: a retrospective observational study. Annals of Lymphoma. https://doi.org/10.21037/aol-20-21

Vancouver

Froukh RFA, Al-Jalil NA, Faqeer N, Ma’koseh M, Al-Rabayah A. Effectiveness and safety of pembrolizumab as bridging to hematopoietic stem cell transplantation in relapsed and refractory classical Hodgkin’s lymphoma: a retrospective observational study. Annals of Lymphoma. 2020. doi:10.21037/aol-20-21

BibTeX
@article{Froukh2020,
  author = {Froukh, Rawan Fawzi Al and Al-Jalil, Noor Abd and Faqeer, Nour and Ma’koseh, Mohammad and Al-Rabayah, Abeer},
  title = {Effectiveness and safety of pembrolizumab as bridging to hematopoietic stem cell transplantation in relapsed and refractory classical Hodgkin’s lymphoma: a retrospective observational study},
  journal = {Annals of Lymphoma},
  year = {2020},
  doi = {10.21037/aol-20-21}
}
Kostenlos starten →